← Eichor
Study identifier: NCT05924100 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD

Condition: Myelodysplastic Syndromes · Del(5Q) · Anemia  ·  Sponsor: Associazione Qol-one

PhasePhase 2
Planned participants22
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Myelodysplastic syndromes, primarily affecting older adults, are a heterogeneous group of clonal disorders of hematopoietic stem cells characterized by ineffective hematopoiesis that manifest clinically as anemia, neutropenia, and/or thrombocytopenia of variable severity; these often result in RBC- transfusion dependent (TD) anemia, increased risk of infection, and/or hemorrhage, as well as a potential to progress to acute myeloid leukemia (AML). Lenalidomide is approved for red blood cell transfusion-dependent (RBC TD) anemia due to low-risk myelodysplastic syndromes (MDS) with a chromosome 5q deletion (del5q) with or without additional cytogenetic abnormalities. About one third of patients are refractory/resistant/intolerant and will require further treatment options. Luspatercept (ACE-536), an erythroid maturation agent, is a recombinant fusion protein consisting of a modified form of the extracellular domain (ECD) of the human activin receptor type IIB (ActRIIB) linked to the Fc portion of human immunoglobulin G1 (IgG1-Fc). Luspatercept acts on endogenous inhibitors of late-stage erythropoiesis (eg, growth differentiation factor 11, GDF11) to increase release of mature erythrocytes into circulation. Nonclinical data have demonstrated that luspatercept binds to negative regulators governing late-stage erythroid development to inhibit their action, thereby promoting the maturation of erythrocytes in the bone marrow. Luspatercept is indicated for the treatment of adult pa…

This description comes directly from the study's public registry record.

Talk to the study team

Esther N Oliva, MD  ·  +393298699514  ·  trials@qol-one.org

Always discuss trial participation with your own doctor first.

Locations (23)

A.O. SS. Antonio e Biagio e Cesare Arrigo Ospedale CivileAlessandria, ItalyNot Yet Recruiting
A.O.U. Ospedali RiunitiAncona, ItalyRecruiting
A.O. S. Giuseppe MoscatiAvellino, ItalyNot Yet Recruiting
Ospedale degli InfermiBiella, ItalyNot Yet Recruiting
A.O.U. G. Rodolico San MarcoCatania, ItalyNot Yet Recruiting
ARNAS Garibaldi, PO NesimaCatania, ItalyNot Yet Recruiting
ASL TO 4 - Ospedale ChivassoChivasso, ItalyNot Yet Recruiting
Azienda Ospedaliera AnnunziataCosenza, ItalyNot Yet Recruiting
A.O.U. CareggiFlorence, ItalyNot Yet Recruiting
A.O.U. Federico IINaples, ItalyNot Yet Recruiting
A.O.U. Maggiore della CaritàNovara, ItalyNot Yet Recruiting
A.O.U. Policlinico Paolo GiacconePalermo, ItalyNot Yet Recruiting

+ 11 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05924100